Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Benitec Biopharma ( (BNTC) ) has provided an update.
On July 9, 2025, Benitec Biopharma announced that the sixth and final subject of Cohort 1 was safely treated with a low dose of BB-301 in their Phase 1b/2a Clinical Treatment Study. Following a positive recommendation from the Data Safety Monitoring Board, the company plans to begin enrolling subjects for Cohort 2 in the fourth quarter of 2025. This development marks a significant step in advancing their gene therapy program, potentially enhancing Benitec’s position in the biotechnology industry and offering hope for stakeholders involved in the treatment of OPMD.
The most recent analyst rating on (BNTC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.
Spark’s Take on BNTC Stock
According to Spark, TipRanks’ AI Analyst, BNTC is a Neutral.
The overall stock score reflects significant financial instability and negative valuation metrics. Technical analysis indicates bearish momentum, further weighing on the stock’s outlook. The absence of earnings call data and corporate events does not impact the score.
To see Spark’s full report on BNTC stock, click here.
More about Benitec Biopharma
Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focusing on the development of novel genetic medicines. The company utilizes its proprietary ‘Silence and Replace’ DNA-directed RNA interference platform, which combines RNA interference with gene therapy to create treatments that silence disease-causing genes while delivering wildtype replacement genes. Benitec is developing therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
Average Trading Volume: 104,474
Technical Sentiment Signal: Hold
Current Market Cap: $354.1M
See more data about BNTC stock on TipRanks’ Stock Analysis page.